# US 2012/0251616 A1 · Tocopherols, Tocotrienols, Other Chroman and Side Chain Derivatives and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251616 A1
- Document ID: US20120251616A1
- Status: Published application
- Kind: A1
- Application number: 13/406,893
- Filed: 2012-02-28
- Published: 2012-10-04
- Earliest claimed: 1998-09-23
- Assignees: Research Development Foundation
- Inventors: Bob G. Sanders; Kimberly Kline; Weiping Yu
- Web page: https://patentgrep.com/patent/US20120251616A1

## CPC

- C07D 311/66: with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 215/20: Oxygen atoms
- C07D 215/46: with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
- C07D 311/58: other than with oxygen or sulphur atoms in position 2 or 4
- C07D 311/72: 3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides an antiproliferative compound having a structural formula where X and Y independently are oxygen, nitrogen or sulfur; R1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate, carboxamide, ester, thioamide, thiolacid, thiolester, saccharide, alkoxy-linked saccharide, amine, sulfonate, sulfate, phosphate, alcohol, ethers or nitriles; R2 and R3 are hydrogen or R4; R4 is methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide or amine; and R5 is alkenyl; where when Y is nitrogen, said nitrogen is substituted with R6, wherein R6 is hydrogen or methyl. Also provided are methods for treating a cell proliferative disease and for inducing apoptosis in a cell comprising administering this compound is also provided.

## Claims

### Claim 1

A method for the treatment of a cell proliferative disease comprising administering to an individual a pharmacologically effective dose of a compound having a structural formula
wherein X is oxygen or nitrogen;
Y is oxygen or NR6
R1 is —C1-10alkylene-COOH, —C1-4alkylene-CONH2, —C1-4alkylene-COO—C1-4alkyl, —C1-4alkylene-CON(C1-4alkylene-COOH)2, —C1-4alkylene-OH, —C1-4alkylene-NH3-halo or —C1-4alkylene-OSO2NH(C1-4alkyl), —C1-4alkylene-CO—SH, —C1-4alkylene-CO—S(C1-4alkyl), —C1-4alkylene-CS—NH2, —C1-4alkylene-CO—NH(2-n)(C1-4alkyl)n wherein n is 2 or 1, —C1-4alkylene-SO2—O(C1-4alkyl), —C1-4alkylene-OSO2—O(C1-4alkyl), —C1-4alkylene-OP(O—C1-4alkyl)3, or —C1-10alkylene-CN;
R2 and R3 are independently hydrogen or R4 when R7 is —XR1; or
R2 and R3 are hydrogen or R2 and R3 are R4 or R2 is hydrogen and R3 is R4 when R7 is hydroxyl;
R4 is methyl;
R5 is a C7-16 olefinic group containing 3 to 5 ethylenic bonds;
R6 is hydrogen or methyl; and
R7 is hydroxyl or —XR1; or a pharmaceutical composition thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein said compound is α-tocotrienol, γ-tocotrienol or δ-tocotrienol.

### Claim 3 (depends on 1)

The method of claim 1, wherein said compound is 2,5,7,8-tetramethyl-2R-(4,8,12-trimethyl-3,7,11 E:Z tridecatrien) chroman-6-yloxy)acetic acid.

### Claim 4 (depends on 1)

The method of claim 1, wherein said compound exhibits an anti-proliferative effect comprising apoptosis, DNA synthesis arrest, cell cycle arrest, or cellular differentiation.

### Claim 5 (depends on 1)

The method of claim 1, wherein said compound is administered in a dose of from about 1 mg/kg to about 60 mg/kg.

### Claim 6 (depends on 5)

The method of claim 5, wherein administration of said composition is selected from the group consisting of oral, topical, liposomal/aerosol, intraocular, intranasal, parenteral, intravenous, intramuscular, or subcutaneous.

### Claim 7 (depends on 1)

The method of claim 1, wherein said cell proliferative disease is a neoplastic disease, a non-neoplastic disease or a non-neoplastic disorder.

### Claim 8 (depends on 7)

The method of claim 7, wherein said neoplastic disease is selected from the group consisting of ovarian cancer, cervical cancer, endometrial cancer, bladder cancer, lung cancer, breast cancer, testicular cancer, prostate cancer, gliomas, fibrosarcomas, retinoblastomas, melanomas, soft tissue sarcomas, ostersarcomas, leukemias, colon cancer, carcinoma of the kidney, pancreatic cancer, basal cell carcinoma, and squamous cell carcinoma.

### Claim 9 (depends on 7)

The method of claim 7, wherein said non-neoplastic disease is selected from the group consisting of psoriasis, benign proliferative skin diseases, ichthyosis, papilloma, restinosis, scleroderma, hemangioma, leukoplakia, viral diseases, and autoimmune diseases.

### Claim 10 (depends on 9)

The method of claim 9, wherein said autoimmune diseases are selected from the group consisting of autoimmune thyroiditis, multiple sclerosis, myasthenia gravis, systemic lupus erythematosus, dermatitis herpetiformis, celiac disease, and rheumatoid arthritis.

### Claim 11 (depends on 5)

The method of claim 5, wherein said non-neoplastic disorder is a viral disorder or an autoimmune disorder.

### Claim 12 (depends on 11)

The method of claim 11, wherein said viral disorder is Human Immunodeficiency Virus.

### Claim 13 (depends on 11)

The method of claim 11, wherein said autoimmune disorder is selected from the group consisting of an inflammatory process involved in cardiovascular plaque formation, ultraviolet radiation induced skin damage and disorders involving an immune component.

### Claim 14

A method of inducing apoptosis of a cell, comprising the step of contacting said cell with a pharmacologically effective dose of the compound having a structural formula
wherein X is oxygen or nitrogen;
Y is oxygen or NR6
R1 is —C1-10alkylene-COOH, —C1-4alkylene-CONH2, —C1-4alkylene-COO—C1-4alkyl, —C1-4alkylene-CON(C1-4alkylene-COOH)2, —C1-4alkylene-OH, —C1-4alkylene-NH3-halo or —C1-4alkylene-OSO2NH(C1-4alkyl), —C1-4alkylene-COO—C1-4alkyl, —C1-10alkylene-CO—SH, —C1-4alkylene-CO—S(C1-4alkyl), —C1-4alkylene-CS—NH2, —C1-4alkylene-CO—NH(2-n)(C1-4alkyl)n wherein n is 2 or 1, —C1-4alkylene-SO2—O(C1-4alkyl), —C1-4alkylene-OSO2—O(C1-4alkyl), —C1-4alkylene-OP(O—C1-4alkyl)3, or —C1-10alkylene-CN;
R2 and R3 are independently hydrogen or R4 when R7 is —XR1; or
R2 and R3 are hydrogen or R2 and R3 are R4 or R2 is hydrogen and R3 is R4 when R7 is hydroxyl;
R4 is methyl;
R5 is a C7-16 olefinic group containing 3 to 5 ethylenic bonds;
R6 is hydrogen or methyl; and
R7 is hydroxyl or —XR1; or a pharmaceutical composition thereof.

### Claim 15 (depends on 14)

The method of claim 14, wherein said compound is α-tocotrienol, γ-tocotrienol or δ-tocotrienol.

### Claim 16 (depends on 14)

The method of claim 14, wherein said compound is 2,5,7,8-tetramethyl-2R-(4,8,12-trimethyl-3,7,11 E:Z tridecatrien) chroman-6-yloxy)acetic acid.

### Claim 17 (depends on 14)

The method of claim 14, wherein said method is useful in the treatment of a cell proliferative disease.
